This is an open-label Phase 2 study evaluating the long term safety and tolerability of GFB-887 in patients with focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD)
Age: 18 - 75 years
Gender: All
We've found 1 total result for "Nephrotic Syndrome".